サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1411730

拡張型心筋症治療薬市場：薬剤クラス別、治療タイプ別、投与経路別、エンドユーザー別、流通チャネル別-2024-2030年の世界予測

Dilated Cardiomyopathy Therapeutics Market by Drug class, Treatment Type, Route of Administration, End-User, Distribution Channel - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 192 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
拡張型心筋症治療薬市場：薬剤クラス別、治療タイプ別、投与経路別、エンドユーザー別、流通チャネル別-2024-2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 192 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

拡張型心筋症治療薬市場規模は2023年に4億2,150万米ドルと推計され、2024年には4億5,676万米ドルに達すると予測され、CAGR 7.79%で2030年には7億1,265万米ドルに達すると予測されます。

拡張型心筋症治療薬の世界市場

主な市場の統計
基準年[2023］ 4億2,150万米ドル
予測年[2024] 4億5,676万米ドル
予測年【2030年 7億1,265万米ドル
CAGR（%） 7.79%
拡張型心筋症治療薬 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは拡張型心筋症治療薬市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、拡張型心筋症治療薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-拡張型心筋症治療薬市場の市場規模および予測は？

2-拡張型心筋症治療薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-拡張型心筋症治療薬市場における技術動向と規制の枠組みは？

4-拡張型心筋症治療薬市場における主要ベンダーの市場シェアは？

5-拡張型心筋症治療薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 心血管疾患の有病率と効果的な治療の必要性
      • 病気の早期診断と治療への傾向
      • 心血管疾患に関する意識を高めるための政府の取り組みとプログラム
    • 抑制要因
      • 拡張型心筋症の治療費は高額
    • 機会
      • 拡張型心筋症の管理における精密医療の応用
      • 拡張型心筋症に対する効率的な薬剤および治療法の開発に向けた継続的な研究開発
    • 課題
      • 拡張型心筋症の治療薬に関連する副作用
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 拡張型心筋症治療薬市場薬剤クラス別

  • アルドステロン拮抗薬
  • アンジオテンシンII受容体遮断薬
  • アンジオテンシン変換酵素（ACE）阻害剤
  • ベータブロッカー

第7章 拡張型心筋症治療薬市場治療タイプ別

  • 除細動器・除細動器
  • 心臓ポンプ
  • 埋め込み型デバイス
  • 薬

第8章 拡張型心筋症治療薬市場：投与経路別

  • オーラル
  • 非経口

第9章 拡張型心筋症治療薬市場：エンドユーザー別

  • 病院
  • 調査機関
  • 専門クリニック

第10章 拡張型心筋症治療薬市場：流通チャネル別

  • 病院薬局
  • オンライン薬局
  • 小売薬局

第11章 南北アメリカの拡張型心筋症治療薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第12章 アジア太平洋地域の拡張型心筋症治療薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第13章 欧州・中東・アフリカの拡張型心筋症治療薬市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第14章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第15章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • AbbVie Inc.
    • Amgen Inc.
    • Amicus Therapeutics
    • Astellas Pharma Inc
    • AstraZeneca plc
    • Bayer AG
    • Biogen Inc.
    • BioMarin Pharmaceutical Inc
    • C.H. Boehringer Sohn AG & Co. KG
    • Daiichi Sankyo Company, Limited
    • Eli Lilly and Company
    • Gilead Sciences, Inc.
    • GlaxoSmithKline（GSK）
    • Johnson & Johnson Services, Inc.
    • Kyowa Kirin Co, Ltd
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • Regeneron Pharmaceuticals, Inc.
    • Roche Holding AG
    • Sanofi S.A.
    • Sarepta Therapeutics
    • Teva Pharmaceutical Industries Ltd.
    • The Bristol-Myers Squibb Company
    • The Takeda Pharmaceutical Company Limited
    • Vertex Pharmaceuticals
    • Viatris Inc.
  • 主要な製品ポートフォリオ

第16章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET DYNAMICS
  • FIGURE 7. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 8. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 10. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 12. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 14. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 16. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 26. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 6. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ALDOSTERONE ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY BETA-BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY CARDIOVERTER-DEFIBRILLATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HEART PUMPS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY IMPLANTABLE DEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 16. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 19. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 235. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 236. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 237. DILATED CARDIOMYOPATHY THERAPEUTICS MARKET LICENSE & PRICING
目次
Product Code: MRR-8E22B61932E2

[192 Pages Report] The Dilated Cardiomyopathy Therapeutics Market size was estimated at USD 421.50 million in 2023 and expected to reach USD 456.76 million in 2024, at a CAGR 7.79% to reach USD 712.65 million by 2030.

Global Dilated Cardiomyopathy Therapeutics Market

KEY MARKET STATISTICS
Base Year [2023] USD 421.50 million
Estimated Year [2024] USD 456.76 million
Forecast Year [2030] USD 712.65 million
CAGR (%) 7.79%
Dilated Cardiomyopathy Therapeutics Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Dilated Cardiomyopathy Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Dilated Cardiomyopathy Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Dilated Cardiomyopathy Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Amicus Therapeutics, Astellas Pharma Inc, AstraZeneca plc, Bayer AG, Biogen Inc., BioMarin Pharmaceutical Inc, C.H. Boehringer Sohn AG & Co. KG, Daiichi Sankyo Company, Limited, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline (GSK), Johnson & Johnson Services, Inc., Kyowa Kirin Co, Ltd, Merck & Co., Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Holding AG, Sanofi S.A., Sarepta Therapeutics, Teva Pharmaceutical Industries Ltd., The Bristol-Myers Squibb Company, The Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals, and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Dilated Cardiomyopathy Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug class
    • Aldosterone antagonists
    • Angiotensin II Receptor Blockers
    • Angiotensin-converting enzyme (ACE) Inhibitors
    • Beta-blockers
  • Treatment Type
    • Cardioverter-Defibrillators
    • Heart Pumps
    • Implantable Devices
    • Medication
  • Route of Administration
    • Oral
    • Parenteral
  • End-User
    • Hospitals
    • Research Institutes
    • Specialty Clinics
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Dilated Cardiomyopathy Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Dilated Cardiomyopathy Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Dilated Cardiomyopathy Therapeutics Market?

4. What is the market share of the leading vendors in the Dilated Cardiomyopathy Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Dilated Cardiomyopathy Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Dilated Cardiomyopathy Therapeutics Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of cardiovascular diseases and the need for effective treatments
      • 5.1.1.2. Inclination toward early diagnosis and treatment of diseases
      • 5.1.1.3. Government initiatives and programs to raise awareness regarding cardiovascular diseases
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of dilated-cardiomyopathy therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Applications of precision medicine in the management of dilated cardiomyopathy
      • 5.1.3.2. Ongoing R&D for the development of efficient drugs and therapies for dilated-cardiomyopathy
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with the dilated-cardiomyopathy medications
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Dilated Cardiomyopathy Therapeutics Market, by Drug class

  • 6.1. Introduction
  • 6.2. Aldosterone antagonists
  • 6.3. Angiotensin II Receptor Blockers
  • 6.4. Angiotensin-converting enzyme (ACE) Inhibitors
  • 6.5. Beta-blockers

7. Dilated Cardiomyopathy Therapeutics Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Cardioverter-Defibrillators
  • 7.3. Heart Pumps
  • 7.4. Implantable Devices
  • 7.5. Medication

8. Dilated Cardiomyopathy Therapeutics Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Oral
  • 8.3. Parenteral

9. Dilated Cardiomyopathy Therapeutics Market, by End-User

  • 9.1. Introduction
  • 9.2. Hospitals
  • 9.3. Research Institutes
  • 9.4. Specialty Clinics

10. Dilated Cardiomyopathy Therapeutics Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacy
  • 10.3. Online Pharmacy
  • 10.4. Retail Pharmacy

11. Americas Dilated Cardiomyopathy Therapeutics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Dilated Cardiomyopathy Therapeutics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Dilated Cardiomyopathy Therapeutics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. FPNV Positioning Matrix
  • 14.2. Market Share Analysis, By Key Player
  • 14.3. Competitive Scenario Analysis, By Key Player

15. Competitive Portfolio

  • 15.1. Key Company Profiles
    • 15.1.1. AbbVie Inc.
    • 15.1.2. Amgen Inc.
    • 15.1.3. Amicus Therapeutics
    • 15.1.4. Astellas Pharma Inc
    • 15.1.5. AstraZeneca plc
    • 15.1.6. Bayer AG
    • 15.1.7. Biogen Inc.
    • 15.1.8. BioMarin Pharmaceutical Inc
    • 15.1.9. C.H. Boehringer Sohn AG & Co. KG
    • 15.1.10. Daiichi Sankyo Company, Limited
    • 15.1.11. Eli Lilly and Company
    • 15.1.12. Gilead Sciences, Inc.
    • 15.1.13. GlaxoSmithKline (GSK)
    • 15.1.14. Johnson & Johnson Services, Inc.
    • 15.1.15. Kyowa Kirin Co, Ltd
    • 15.1.16. Merck & Co., Inc.
    • 15.1.17. Novartis AG
    • 15.1.18. Pfizer Inc.
    • 15.1.19. Regeneron Pharmaceuticals, Inc.
    • 15.1.20. Roche Holding AG
    • 15.1.21. Sanofi S.A.
    • 15.1.22. Sarepta Therapeutics
    • 15.1.23. Teva Pharmaceutical Industries Ltd.
    • 15.1.24. The Bristol-Myers Squibb Company
    • 15.1.25. The Takeda Pharmaceutical Company Limited
    • 15.1.26. Vertex Pharmaceuticals
    • 15.1.27. Viatris Inc.
  • 15.2. Key Product Portfolio

16. Appendix

  • 16.1. Discussion Guide
  • 16.2. License & Pricing